Apellis Pharmaceuticals, Inc.
Board Member
2025-01-08–present
Keli Walbert
Board Member
Apellis Pharmaceuticals, Inc.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Keli Walbert
Keli Walbert is recorded as Board Member at Apellis Pharmaceuticals, Inc.. Apellis Pharmaceuticals, Inc. reported in an 8-K filed May 14, 2026 that Keli Walbert resigned as member of the Board of Directors of the Company and any committee thereof, effective May 14, 2026. Apellis Pharmaceuticals, Inc. reported in an 8-K filed January 13, 2025 that Keli Walbert was appointed Class II director, effective January 8, 2025.
“Effective as of the Effective Time, Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.”
“On January 8, 2025, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Keli Walbert to the Board as a Class II director to serve until the Annual Meeting of Stockholders to be held in 2025 or until her successor has been duly elected and qualified or until her earlier death, resignation or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Apellis Pharmaceuticals, Inc.
Board Member
SEC 8-K
Current2025-01-08–present
-
Apellis Pharmaceuticals, Inc.
Board Member
SEC 8-K
2025-01-08–2026-05-14
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
-
Executive change Resigned: member of the Board of Directors of the Company and any committee thereof
Apellis Pharmaceuticals, Inc.
-